Corcept Therapeutics Reports Earnings Results

Corcept Therapeutics (NASDAQ:CORT) announced its quarterly earnings on Wednesday. For the past quarter, the biotechnology company recorded earnings of $0.26 per share (EPS). This result was below the analysts' expectations, which were predicted at $0.37 per share, marking a miss of $0.11. Additionally, Corcept Therapeutics achieved a net margin of 22.35% and a return on equity of 24.54%. Following these results, the company updated its earnings guidance for the fiscal year 2025.

Corcept Therapeutics Price Performance

On Wednesday, shares of Corcept Therapeutics traded up by $2.14, reaching a price of $63.37. A total of 1,315,439 shares changed hands during the trading day, which is higher than its average trading volume of 921,919 shares. The company's 50-day moving average price is $59.60, while the two-hundred-day moving average price stands at $51.16. Corcept Therapeutics has a low of $20.84 and a high of $75.00 over the last year. The company is valued at $6.64 billion, with a price-to-earnings ratio of 50.29 and a beta of 0.58.

Analyst Ratings Changes

Recent reports from several equity analysts have been released concerning Corcept Therapeutics. HC Wainwright reaffirmed a "buy" rating and set a target price of $80.00 for the company's shares. In a more recent note dated November 25th, StockNews.com downgraded Corcept Therapeutics from a "strong-buy" rating to a "buy" rating. On January 30th, Canaccord Genuity Group raised their price objective for Corcept Therapeutics from $78.00 to $130.00, maintaining a "buy" rating. Overall, six research analysts have rated the stock as a buy, and it currently holds an average rating of "Buy" with a target price of $88.25 according to MarketBeat data.

Insider Activity

In recent insider trading news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company stock on February 10th for an average price of $68.08, resulting in a transaction value of $149,776.00. The details of this sale were filed with the SEC and are accessible in public records. Additionally, insider Sean Maduck sold 20,000 shares of his stock on January 2nd at an average price of $50.39, totaling $1,007,800. Following this transaction, Maduck holds 85,318 shares valued at approximately $4.3 million. In total, insiders have sold 26,600 shares worth $1,399,576 over the past 90 days, maintaining insider ownership at 20.50% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a biotechnology company engaged in the discovery and development of pharmaceuticals for the management of severe endocrinologic, oncologic, metabolic, and neurologic diseases in the United States. One of their key products is Korlym, a medication that treats hyperglycemia linked to hypercortisolism in adult patients with endogenous Cushing’s syndrome, particularly those who also have type 2 diabetes or glucose intolerance and are not eligible for surgery.

Earnings, Biotechnology, Stocks